Duality Biologics

Shanghai Henlius Biotech is trying to play a David versus Goliath game of catch-up with Pfizer, in pursuit of the commercialization of the world’s first PD-L1-targeting antibody-drug conjugate (ADC).

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A

Who: GSK and Relation Therapeutics What: The UK major has linked up with fellow London-based group Relation on two “multi-program strategic collaborations” which will focus on the identification an

Antibody-drug conjugate (ADC) developer Adcendo has been busy during the last year and a half since the company raised a €31m ($32.3m) extension of the €51m ($53.2m) series A it originally raised in 2